Global Cold Chain Logistics for Biologics and Cell Therapy Market Strategic Research Report

The global cold chain logistics market for biologics and cell therapy occupies a critical position at the intersection of advanced medicine and precision supply chain management. Valued at approximately USD 22.4 billion in 2024, this market underpins the safe transport and storage of temperature-sensitive pharmaceutical products including monoclonal antibodies, vaccines, gene therapies, CAR-T cell therapies, and plasma-derived biologics. As the biopharmaceutical pipeline expands at an unprecedented rate — with over 1,200 biologic therapies in clinical development globally as of 2024 — the infrastructure required to maintain strict temperature integrity from manufacturing site to patient bedside has become a strategic priority for pharmaceutical manufacturers, contract logistics providers, and healthcare systems alike. The market's complexity is amplified by the extreme temperature requirements of cell and gene therapies, many of which demand cryogenic storage at -80°C or below, placing extraordinary demands on packaging, transport equipment, and monitoring technology.

Three converging forces are accelerating market expansion through the forecast period. First, the commercial approval and scaling of autologous and allogeneic cell therapies — including CAR-T products such as Kymriah and Yescarta — requires highly specialized, time-critical logistics chains that are fundamentally different from conventional pharmaceutical distribution, creating demand for bespoke infrastructure and service capabilities. Second, the geographic expansion of biologic manufacturing into Asia Pacific, particularly in China, South Korea, and India, is extending cold chain networks across new corridors and compelling logistics providers to build or acquire regional cryogenic and controlled-rate infrastructure. Third, tightening regulatory scrutiny from agencies including the FDA, EMA, and WHO on temperature excursion documentation and chain-of-custody validation is compelling shippers to upgrade from passive to active and hybrid temperature-controlled packaging solutions. The principal market restraint remains the acute shortage of qualified cold chain professionals — particularly those trained in cryogenic handling and GxP-compliant documentation — which constrains capacity growth and inflates service costs across established markets.

This report delivers a comprehensive, data-anchored analysis of the global cold chain logistics market for biologics and cell therapy, covering market sizing from 2019 through 2032, segmentation by logistics type, temperature range, end-use application, and geography across six regions and six priority countries. The report profiles ten leading companies with revenue context, competitive positioning, and recent strategic actions. It is designed for corporate strategy teams evaluating capacity investments, investment analysts assessing logistics sector exposure to the biopharma growth wave, M&A advisors identifying consolidation targets, and procurement managers benchmarking service provider capabilities.